Hepatitis B virus (HBV) transgenic mice whose hepatocytes replicate the virus at levels comparable to that in the infected livers of patients with chronic hepatitis have been produced, without any evidence of cytopathology. High-level viral gene expression was obtained in the liver and kidney tissues in three independent lineages. These animals were produced with a terminally redundant viral DNA construct (HBV 1.3) that starts just upstream of HBV enhancer I, extends completely around the circular viral genome, and ends just downstream of the unique polyadenylation site in HBV. In these animals, the viral mRNA is more abundant in centrilobular hepatocytes than elsewhere in the hepatic lobule. High-level viral DNA replication occurs inside viral nucleocapsid particles that preferentially form in the cytoplasm of these centrilobular hepatocytes, suggesting that an expression threshold must be reached for nucleocapsid assembly and viral replication to occur. Despite the restricted distribution of the viral replication machinery in centrilobular cytoplasmic nucleocapsids, nucleocapsid particles are detectable in the vast majority of hepatocyte nuclei throughout the hepatic lobule. The intranuclear nucleocapsid particles are empty, however, suggesting that viral nucleocapsid particle assembly occurs independently in the nucleus and the cytoplasm of the hepatocyte and implying that cytoplasmic nucleocapsid particles do not transport the viral genome across the nuclear membrane into the nucleus during the viral life cycle. This model creates the opportunity to examine the influence of viral and host factors on HBV pathogenesis and replication and to assess the antiviral potential of pharmacological agents and physiological processes, including the immune response.
The hepatitis B virus (HBV) contains a small (3.2-kb), circular, double-stranded DNA genome and causes acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma (10) . Because of the limited host range of HBV and the inability to grow it in vitro, much of what is known about the HBV life cycle has come from studies of other members of the hepadnavirus family, especially the woodchuck hepatitis virus and the duck hepatitis B virus, which infect their native species and, in the case of the duck hepatitis B virus, can be grown in tissue culture (34) .
On the basis of circumstantial evidence, it is generally accepted that HBV is not directly cytopathic for the hepatocyte and that the antiviral immune response is responsible for the associated liver disease during HBV infection (5) . This concept has not been directly testable until recently, however, because the immunobiology of woodchuck hepatitis virus and that of duck hepatitis B virus are not well defined because of the outbred nature of their natural hosts. We and others, therefore, set out several years ago to develop HBV transgenic mice to permit these, and other, complex biological questions to be addressed in a well-defined, inbred, small-animal system.
As a result of those studies, many transgenic lineages that express the HBV envelope (2, 3, 6, 7, 11) , core (13, 25) , precore (26) and X (20, 22) proteins under the control of HBV or cellular liver-specific promoters have been described in recent years. Much has been learned about the assembly, transport, secretion, and other functional properties of these proteins and about the induction, the characteristics, and the consequences of the corresponding immune responses in those animals. Such animals are not suitable, however, for studies of viral replication, since they express only a single gene product and cannot replicate the virus.
To address this important question, other investigators produced transgenic mice using constructs structurally capable, as linear molecules, of transcribing all of the viral gene products simultaneously (1, 9) . While these animals clearly demonstrated that HBV can replicate in the murine hepatocyte, their further experimental value has been limited because they replicate the virus at very low levels (1, 9) and because in one instance (9) the transgene was not transmitted through the germ line.
Over the past several years, we have produced transgenic mice with a series of terminally redundant, greater-than-genome length constructs with the hope of identifying a DNA structure that would drive HBV expression and replication at levels comparable to that in naturally infected liver. All constructs shared a common 3Ј terminus at nucleotide (nt) 1982, just downstream of the unique polyadenylation site in the HBV genome, and they were made to differ in overall length by positioning their 5Ј termini either just upstream of the nucleocapsid promoter and enhancer II (1.1 genome eq), in the middle of the X gene (1.2 genome eq), or just upstream of the X promoter and enhancer I (1.3 genome eq).
We now report that very-high-level HBV replication has been achieved in the liver and kidney tissues of three independent lineages containing the 1.3 genome eq construct while only low-level, kidney-preferential replication occurred with the shorter constructs. This article describes the salient characteristics of this model. The results illustrate that high-level HBV replication is not cytopathic for the murine hepatocyte, and they highlight several important aspects of the HBV life cycle that are not widely appreciated. Perhaps most importantly, this model creates the opportunity to examine many aspects of HBV immunobiology and pathogenesis that have not been heretofore analyzable.
MATERIALS AND METHODS
Transgenic mice. The HBV transgenic mice used in these studies were produced by microinjection of the HindIII-SacI fragment excised from plasmids pT-HBV1.1, pT-HBV1.2, and pT-HBV1.3 ( Fig. 1 ) into either (C57BL/6 ϫ SJL)F 2 embryos or inbred B10.D2 embryos by conventional technology as previously described (2) . Plasmids pT-HBV1.1, pT-HBV1.2, and pT-HBV1.3 contain overlength HBV genomes, differing 5Ј terminally by the size of the redundancy but all terminating at a unique SacI site introduced downstream of the polyadenylation signal (17) . Each HBV genome was preceded by a unique HindIII cleavage site introduced at position 1640 in pT-HBV1.1, position 1393 in pT-HBV1.2, and position 1068 in pT-HBV1. 3 . Founder animals were screened by analysis of serum for hepatitis B surface antigen (HBsAg) and HBeAg using commercially available reagents (Abbott Laboratories, Abbott Park, Ill.) as previously described (6) , and animals that were positive for both antigens were bred for analysis. Lineages 1. In selected experiments, liver tissue derived from transgenic-mouse lineages 1.2HBBS (1) and PC21 (9) , generously provided by Kenichi Yamamura (Institute for Medical Genetics, Kumamoto University Medical School, Kumamoto, Japan) and by Christine Pourcel (Institut de Biologie, Nantes, France), respectively, were also studied. Lineage 1.2HBBS was produced by microinjection of a terminally redundant, greater-than-genome length fragment representing 1.19 copies of the HBV genome that extends between nt 1272 and 1891 (in which the unique XhoI site is designated nt 1) of HBV (adr4 subtype) (1) . Lineage PC21 contains a HindIII-PstI fragment representing a complete dimer of the HBV genome (ayw subtype) in which the entire HBV genome was cloned in a headto-tail arrangement at the EcoRI site (nt 1 in Galibert sequence terminology) of pBR322 (9) .
Serum from transgenic lineage pFC80-219 (11) (official designation, Tg[HBs, HBV]Chi 219) was also used for comparative purposes in selected assays. This lineage expresses only the 2.1-kb HBV mRNA and secretes HBsAg at a high level in the serum (11) .
In all experiments, mice were anesthetized with Metophane (Pitman-Moore, Mundelein, Ill.) prior to phlebotomy from the retro-orbital plexus and before they were sacrificed by cervical dislocation.
Human liver tissue. Autopsy-derived liver tissue from six HBV-infected patients with chronic active hepatitis and cirrhosis were provided by John Brems (Scripps Clinic and Research Foundation), Michael Gerber (Tulane University Medical Center), and David Shafritz (Albert Einstein College of Medicine). All tissues were stored at Ϫ70ЊC until use. HBV DNA analysis. (i) DNA isolation and southern blot analysis. Southern blot analysis was performed on total genomic DNA by agarose gel electrophoresis of 20 g of restricted genomic DNA as previously described (23) . Before electrophoresis, all DNA samples were digested with RNase A (Boehringer Mannheim, Indianapolis, Ind.) at 10 g/ml for 1 h at 37ЊC. Nylon filters were hybridized either with HBV-specific 32 P-radiolabeled DNA probes as previously described (12) or with 33 P-radiolabeled strand-specific RNA probes that were also used for in situ hybridization analysis (described below).
(ii) PCR analysis of the integrated transgene. Total liver genomic DNA (1 g) from lineages 1.3.32 and 1.3.46 was analyzed by PCR using HBV-specific primers (5Ј-CTAAGCAGGCTTTCACTTTC [sense, nt 1077 to 1096] and 5Ј-CAGA AAGGCCTTGTAAGTTG [antisense, nt 1120 to 1101]). Twenty-microliter samples of the products from direct PCR amplifications were analyzed by electrophoresis on a 1% agarose gel in the presence of 0.5 g of ethidium bromide per ml. DNA bands were visualized by UV fluorescence.
(iii) Subcellular localization of replicative forms of HBV DNA. Viral DNA contained in the nucleus was analyzed as follows. Nuclei from liver samples were purified exactly as described previously (15) . Briefly, liver samples were homogenized by 10 to 20 strokes in a Potter-Elvehjem tissue grinder in 5 ml of buffer A (60 mM KCl, 15 mM NaCl, 0.15 mM spermine, 0.5 mM spermidine, 14 mM 2-mercaptoethanol, 0.5 mM EGTA [ethylene glycol-bis(␤-aminoethyl ether)-N,N,NЈ,NЈ-tetraacetic acid], 2 mM EDTA, 0.3 M sucrose, 15 mM Tris Cl [pH 7.5]), and centrifuged over a 5-ml cushion of buffer B (60 mM KCl, 15 mM NaCl, 0.15 mM spermine, 0.5 mM spermidine, 14 mM 2-mercaptoethanol, 0.5 mM EGTA, 2 mM EDTA, 0.85 M sucrose, 15 mM Tris Cl [pH 7.5]) at 100,000 ϫ g for 20 min at 4ЊC. The pellet was resuspended in 3 ml of buffer C (60 mM KCl, 15 mM NaCl, 0.15 mM spermine, 0.5 mM spermidine, 14 mM 2-mercaptoethanol, 0.1 mM EGTA, 0.1 mM EDTA, 2 M sucrose, 15 mM Tris Cl [pH 7.5]) and centrifuged over an 8-ml cushion of buffer C in a Beckman SW40 rotor at 36,000 rpm for 1 h at 4ЊC. Nuclei were counted and resuspended in 1 ml of Tris-EDTA buffer (10 mM Tris-acetate [pH 8], 10 mM EDTA), and Nonidet P-40 (Sigma, St. Louis, Mo.) (final concentration, 0.5%) was added for 30 min on ice. After magnesium acetate (final concentration, 5 mM) was added, the nuclei were digested with RNase A (Boehringer Mannheim) at 10 g/ml and with 20 U of DNase I (Boehringer Mannheim) per ml for 1 h at 37ЊC. Subsequently, EDTA (final concentration, 10 mM), sodium dodecyl sulfate (SDS) (final concentration, 1%), NaCl (final concentration, 0.1 M), and pronase E (Sigma) (final concentration, 0.5 mg/ml) were added sequentially, and the samples were incubated for 3 to 4 h at 42ЊC. The samples were then extracted with phenol-chloroform, ethanol precipitated and quantitated, and DNA extracted from 8 ϫ 10 6 nuclei was loaded into the gel and analyzed by Southern blot (23) .
DNA contained in the cytoplasm was analyzed essentially as described previously (31) . Briefly, 120 mg of liver tissue was homogenized by 10 to 20 strokes in a Potter-Elvehjem tissue grinder in 2 ml of ice-cold Tris-EDTA buffer. One milliliter was used for analysis of viral cytoplasmic DNA, and the other milliliter was used for analysis of covalently closed circular DNA (cccDNA) (see below). Nonidet P-40 (final concentration, 0.5%) was added to 1 ml of liver homogenates, and after a 30-min incubation on ice the samples were centrifuged to remove the nuclei and cellular debris. Magnesium acetate (final concentration, 5 mM) was then added, and the supernatants were incubated for 30 min at 37ЊC with 20 U of DNase I per ml. Subsequently, EDTA (final concentration, 10 mM), SDS (final concentration, 1%), NaCl (final concentration, 0.1 M), and pronase E (final concentration, 0.5 mg/ml) were added sequentially, and the samples were incubated for 3 to 4 h at 42ЊC. The samples were then extracted with phenolchloroform, ethanol precipitated, quantitated, and digested with RNase A, and an amount of cytoplasmic extract derived from 4 ϫ 10 5 liver cells was analyzed by Southern blot.
(iv) Analysis of HBV cccDNA by Southern blot. Isolation of cccDNA was performed essentially as described elsewhere (4) . Briefly, SDS was immediately added (final concentration, 2%) to 1 ml of the liver extract described above. Cellular DNA, proteins, and viral protein-bound DNA were precipitated with FIG. 1. A schematic representation of the HBV genome (ayw subtype) used in this study is shown at the top. Schematic representations of the HBV-derived constructs that contain terminally redundant, greater-than-genome length (1.1-, 1.2-, 1.3-eq) copies of the complete HBV genome used for the generation of HBV transgenic mice are shown below. Enh. and En, enhancer; Poly A, polyadenylation signal; X, C, PS, and S, X, core, pre-S, and S promoter, respectively.
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KCl (final concentration, 0.5 M). After centrifugation, the supernatant was extracted with phenol-chloroform, ethanol precipitated, quantitated, digested with RNase A, and analyzed by Southern blot.
(v) Structural analysis of replicative forms of HBV DNA. Viral DNA contained in cytoplasmic core particles was quantitated and digested with RNase A as described above and either heated at 100ЊC for 5 min, treated with Klenow polymerase (Boehringer Mannheim) for 1 h at 37ЊC according to the manufacturer's instructions, or digested with selected restriction enzymes before Southern blot analysis.
Analysis of HBV gene expression. (i) Northern blot analysis. Frozen tissues were mechanically pulverized and extracted by the acid-guanidium-phenol-chloroform method (8) . Total RNA (20 g) was analyzed for HBV and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression by Northern (RNA) blot as previously described (12) .
(ii) Primer extension analysis. Total liver RNA was extracted as described above. Fifty micrograms of total liver RNA was subjected to primer extension with 10 U of Moloney murine leukemia virus reverse transcriptase (Boehringer Mannheim) and 5 ng of gel-purified oligonucleotides that were 32 P labeled at the 5Ј end with T4 polynucleotide kinase (New England Biolabs, Beverly, Mass.). The samples were electrophoresed on a denaturing 6% polyacrylamide gel and exposed to X-ray film (Kodak, Rochester, N.Y.). The primer for the HBV 2.4-kb mRNA (5Ј CCTTGTTGGGATTGAAGTCCCAATCTGGATTTGCG, nt 1395 to 1361) is designed to give an extension product of 153 bases, while the primer for the HBV 0.7-kb mRNA (5Ј TTGGCAGCACAGCCTAGCAGCCATGGAA ACGATGT, nt 2392 to 2368) should produce several extension products ranging from about 178 to 130 bases in keeping with the multiple start sites previously mapped for these transcripts (32) .
(iii) In situ hybridization. Snap frozen liver sections (thickness, 5 m) were transferred to polylysine-coated slides and fixed in a 4% paraformaldehydephosphate-buffered saline (PBS) solution for 20 min at room temperature. The fixed sections were briefly washed in PBS at room temperature and dehydrated by sequential transfer through 30, 70, and 90% ethanol baths. After digestion with pronase E (Sigma) at 0.35 mg/ml in PBS for 10 min at room temperature, the slides were refixed in 4% paraformaldehyde-PBS as above and acetylated by 0.25% acetic anhydride (Sigma) in 0.1 M triethanolamine (Sigma). The sections were then washed in PBS and dehydrated by sequential transfer through 30, 70, 90, and 100% ethanol baths. Hybridization buffer (50% formamide, 12.5% dextran sulfate, 2ϫ SSC [1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 1ϫ Denhardt's solution, 10 mM dithiothreitol [DTT], 1 mM EDTA, 250 g of yeast tRNA per ml containing 20 ϫ 10 6 cpm of alkaline digested probe per ml) was added to each section, and the samples were covered with Parafilm and incubated overnight at 50ЊC in a humidified chamber. The slides were then washed for 3 h at 52ЊC in buffer A (50% formamide, 2ϫ SSC, 1ϫ Denhardt's solution, 10 mM DTT) and for 15 min at 37ЊC in buffer B (1 M Tris-HCl [pH 8], 0.5 M EDTA, 0.5 M NaCl). The sections were digested with RNase A (20 g/ml) in buffer B for 30 min at 37ЊC and then washed in buffer B for 30 min at 37ЊC. Remaining free radioactivity was removed by washing in 2ϫ SSC for 30 min at room temperature and 0.1ϫ SSC for 30 min at room temperature. The sections were then dehydrated in graded ethanol as above, dipped in Kodak NTB-2 emulsion (diluted 1:1 with 0.6 M ammonium acetate), developed after 24 to 48 h of exposure, and counterstained with hematoxylin and eosin. The 33 P-labeled RNA probes used for in situ hybridization were generated by in vitro transcription (Transcription kit; Boehringer Mannheim) of 1 g of the DNA template. A 0.75-kb fragment which spans sequences on the noncoding and coding strands of HBV between residues 1243 and 1948 was subcloned from an EBO vector previously described (14) into the KpnI-SacI site of pBluescript SKII. The plasmid was linearized with KpnI or SacI to yield the sense and antisense probes. A 0.66-kb fragment which spans sequences on the noncoding strand of HBV between residues 2139 and 2800 was subcloned from an EBO vector previously described (14) into the XbaI-SalI site of pBluescript SKII. The plasmid was linearized with NotI or EcoRI to yield the sense and antisense probes. The 33 P-labeled RNA probes were digested in an alkaline buffer (10 mM EDTA, 10 mM Tris-HCl [pH 7.4], 0.2% SDS, 12.5 mM DTT, 100 mM NaCl, 250 mM NaOH) for 45 min on ice and extracted with phenol-chloroform. Free radioactivity was removed by passing the probes through a Sephadex G-50 column (Pharmacia Biotech, Uppsala, Sweden), and the probes were ethanol precipitated and resuspended in diethyl pyrocarbonate-treated water.
(iv) Immunoblot analysis. Serum and organ homogenates were prepared as described elsewhere (24) . Total soluble protein was determined by Coomassie blue G-250 binding (Bio-Rad). Precore, core envelope, and X proteins were analyzed by Western blot (immunoblot) as previously described (1, 13) . Briefly, 100 g of total liver protein extract was separated by SDS-15% polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (Amersham, Arlington Heights, Ill.). To detect core and precore antigens, rabbit anti-HBc/ eAg (Dako, Carpinteria, Calif.) primary antiserum was applied at a 1:500 dilution, and then a 125 I-labeled anti-rabbit whole antibody (Amersham) was used. To detect envelope antigens, goat anti-HBsAg (Dako) primary antiserum was applied at a 1:500 dilution, and then a biotinylated anti-goat whole antibody (Dako) and streptavidin-horseradish peroxidase conjugate (Amersham) was used. To detect the HBV X protein, mouse monoclonal anti-X antibodies (11/ S1/G5 and 11/4/80, generously provided by Claus H. Schröder, Angewandte Tumorvirologie, Heidelberg, Germany) were applied at a 1:100 dilution, and then a 125 I-labeled anti-mouse whole antibody (Amersham) was used. Total liver protein extracts from nontransgenic littermates were used as negative controls. Recombinant HBeAg and recombinant HBcAg (Sorin, Saluggia, Italy), total liver protein extracts from lineage 50-4, which overexpresses all envelope proteins (6), and total protein extracts from JY cells infected with recombinant vaccinia virus encoding the HBV X protein were used as positive controls for HBe/cAg, HBsAg, and HBV X protein, respectively.
(v) Histological analysis. Tissue samples were fixed in 10% zinc-buffered formalin (Anatek, Battle Creek, Mich.), embedded in paraffin, sectioned (3 m), and stained with hematoxylin and eosin as described elsewhere (6) .
(vi) Immunohistochemical analysis. The intracellular distribution of HBcAg was assessed by the labeled-avidin-biotin detection procedure exactly as described elsewhere (13) . Briefly, paraffin-embedded sections in PBS, pH 7.4, were treated for 10 min at 37ЊC with 3% hydrogen peroxide and washed with PBS. After the sections were blocked with normal goat serum for 30 min at room temperature, rabbit anti-HBc/eAg (Dako) primary antiserum was applied at a 1:100 dilution for 60 min at 37ЊC (HBcAg). After a wash with PBS, a secondary antiserum consisting of biotin-conjugated goat anti-rabbit immunoglobulin G F(abЈ) 2 (Sigma) was applied at a 1:100 dilution for 30 min at 37ЊC. The antibodycoated slides were washed with PBS, treated with the streptavidin-horseradish peroxidase conjugate (Extravidin; Sigma) at a 1:600 dilution for 30 min at 37ЊC, stained with 3-amino-9-ethyl carbazole (AEC; Shandon-Lipshaw, Pittsburgh, Pa.), and counterstained with Mayer's hematoxylin before being mounted. The intracellular distribution of HBsAg was assessed by the indirect immunoperoxidase method, using 3-amino-9-ethyl carbazole as a coloring substrate, as previously described (6) .
(vii) Serological analysis. Serum HBsAg and HBeAg concentrations were determined as follows. Two pools of serum were prepared from 30 age-and sex-matched transgenic mice from lineages 1.3.32 and 1.3.46 and analyzed for HBsAg and HBeAg by using commercially available reagents (Abbott Laboratories). HBsAg and HBeAg were quantitated by comparison with serial dilutions of known standards (Abbott Laboratories and Sorin).
The concentration of pre-S1 in serum was determined as follows. Serum was pooled as described above and analyzed for the presence of the HBV pre-S1 antigen by enzyme-linked immunosorbent assay. Briefly, plates (Falcon 3912; Becton Dickinson, Oxnard, Calif.) were coated with 100 l of a mouse monoclonal anti-pre-S1 antibody (MA18/7, generously provided by Wolfram Gerlich, Universitat Giessen, Giessen, Germany) at 1 g/ml in PBS for 1 h at 37ЊC. After being blocked for 15 min at room temperature with 1% bovine serum albumin (BSA) in PBS, the wells were washed twice with 1% BSA in 0.05% Tween 20-PBS, and 50 l of transgenic-mouse serum, HBV-infected human serum, or recombinant small or recombinant large envelope protein (Merck, West Point, Pa.) was added for 1 h at 37ЊC. The wells were washed as above, and 100 l of 125 I-labeled anti-HBsAg antibody (provided in a commercially available kit [Abbott Laboratories]) was added for 1 h at 37ЊC. The wells were then washed three times with 1% BSA in 0.05% Tween 20-PBS and counted for ␥-emission in a Packard gamma counter (Packard, Downers Grove, Ill.). HBV-infected human serum was also used for comparative purposes in selected assays.
(viii) Quantitation of the HBV DNA concentration in serum. The concentration of HBV DNA in transgenic-mouse serum was determined by two different quantitative dot blot procedures in our laboratories. In the first procedure (performed in La Jolla, Calif.), 300 l of filtered transgenic-mouse serum pooled from lineages 1.3.32 and 1.3.46 was incubated for 1 h at 37ЊC with 50 l of 50 mM magnesium acetate, and 200 U of DNase I. As a negative control, filtered transgenic-mouse serum pooled from a lineage (pFC80-219) that does not replicate the viral genome was also included but not digested with DNase. EDTA (final concentration, 10 mM), SDS (final concentration, 1%), NaCl (final concentration, 0.1 M), and pronase E (final concentration, 0.5 mg/ml) were added sequentially, and the samples were incubated for 3 to 4 h at 42ЊC. The samples were then extracted with phenol-chloroform, ethanol precipitated, resuspended in Tris-EDTA, and applied with vacuum to a nylon membrane. After denaturation with 0.5 N NaOH, the filters were neutralized and hybridized with a specific radiolabeled HBV DNA probe. The hybridization signal was compared with the signal of a serially diluted plasmid DNA (pFC80) that contains four complete HBV genomes (ayw subtype) (11) and quantitated by the Matrix 96 Beta Counter (Packard).
Independently, in Heidelberg, the concentration of HBV DNA in a separate pool of transgenic-mouse serum from lineage 1.3.32 was compared with that in acutely HBV-infected-chimpanzee serum (35) . Briefly, 100-l samples of transgenic-mouse and HBV-infected-chimpanzee sera were cleared by centrifugation at 13,000 rpm for 1 min, and viral particles were pelleted by ultracentrifugation in a TLA 45 rotor at 44,000 rpm for 1 h. The pellet was dissolved in 100 l of 10 mM Tris HCl, (pH 7.6)-0.1 M NaCl, denatured with NaOH (final concentration, 0.1 M), and adsorbed by filtration to a nylon membrane. The filters were neutralized and hybridized with a specific 32 P-labeled HBV DNA probe. The hybridization signal was compared with the signal of a serially diluted plasmid HBV DNA standard (ayw subtype).
(ix) Serum endogenous polymerase activity. The endogenous polymerase activity of transgenic-mouse serum was compared with that in serum from an acutely HBV-infected chimpanzee (35) with a known HBV DNA concentration (see above). One milliliter of pooled transgenic-mouse serum from lineage 1.3.32 and 100 l of HBV-infected-chimpanzee serum were pelleted as described above, and DNA was 32 P radiolabeled by the endogenous polymerase reaction exactly as described elsewhere (27) . The 32 P-radiolabeled endogenously elongated HBV DNA products were analyzed by electrophoresis in a 1.5% agarose gel containing 1% SDS before and after digestion with selected restriction enzymes and analyzed by 1.5% agarose gel containing 1% SDS.
(x) Electron microscopy. Intracellular nucleocapsid particles were analyzed exactly as described elsewhere (13) . Briefly, thin liver sections were fixed overnight at 4ЊC in 4% paraformaldehyde-0.1% glutaraldehyde in PBS. Sections were then postfixed in 1% OsO 4 in cacodylate buffer (pH 7.4) for 1 h at room temperature, dehydrated in gradient ethanol, and embedded in epoxy resin (TAAB 812; Emmer Green, Reading, England). Sections were cut on an LKB Ultratome III, mounted on copper grids, stained in uranyl acetate and lead citrate, and viewed with a Hitachi HU 12-A electron microscope.
Serum-derived virus particles were analyzed as follows. Five hundred microliters of transgenic-mouse serum was centrifuged (200,000 ϫ g) overnight at 14ЊC through 2.4 ml of 10% sucrose into 0.8 ml of 60% sucrose. Fractions (100 l) were collected from the bottom, and the first fraction (positive for endogenous polymerase activity) was incubated for 45 min at room temperature on MA18/ 7-coated (100 g/ml) Parlodion-carbon-coated nickel grids that were subsequently drained with a piece of filter paper and washed twice in PBS. The grids were then fixed in 1.5% glutaraldehyde for 2 to 5 min, washed twice in H 2 O, negatively stained with uranyl acetate, and viewed with a Hitachi HU 12-A electron microscope. As positive control, Dane particles (see Results) purified from infected human sera (generously provided by John Gerin, Georgetown University, Washington, D.C.) were subjected to the same procedure.
RESULTS
Founder animals. A total of nine founder animals whose sera were positive for both HBsAg and HBeAg were produced with the 1.1 (five founders), 1.2 (one founder), and 1.3 (three founders) HBV genome constructs (Fig. 1) . By Northern and Southern blot analysis of tissues from the 1.1 and 1.2 genome animals, only low-level, kidney-preferential HBV expression and replication were observed (not shown), and these animals were not studied further. Because we observed high-level HBV gene expression and viral replication in the liver in the three lineages containing the 1.3 genome construct (designated lineages 1.3.2, 1.3.32, and 1.3.46), these animals were studied in greater detail. Founder 1.3.2 was infertile, so all subsequent analysis was performed with the progeny of founders 1.3.32 and 1.3.46, produced by mating the founders to nontransgenic C57BL/6 and B10.D2 mice, respectively.
Analysis of the integrated transgene. (i) Transgene integration site. Total DNA was isolated from liver and kidney tissues of lineages 1.3.32 and 1.3.46, digested with an enzyme (HindIII) that does not cut within the transgene, and analyzed by Southern blot. As shown in Fig. 2A , we detected a single slowly migrating band for lineages 1.3.32 and 1.3.46, indicating that the transgenes are integrated at a single site. The estimated size of the integrated transgene in lineage 1.3.32 was less than 8 kb (Fig. 2) , suggesting that a single copy of the microinjected 1.3 HBV construct (4,096 bp) may be integrated in this lineage (see below). Abundant lower-molecular-weight species representing replicating forms of HBV DNA were also detected in these tissues and will be discussed below.
(ii) Transgene structure and copy number. To determine the structure and copy number of the integrated transgene in lineages 1.3.32 and 1.3.46, we carried out a PCR-based strategy using HBV-specific sense and antisense nonoverlapping primers located at the 5Ј end of the terminal redundancy in the microinjected construct. These primers amplified in lineage 1.3.32 only a 3.2-kb product (not shown), indicating that a single uninterrupted copy of the construct is integrated at a single site in the mouse genome (see also above). When the same primers were used to analyze lineage 1.3.46, in addition to this 3.2-kb band we observed a ϳ950-bp product, indicating that two or more uninterrupted copies of the transgene are integrated in a head-to-tail orientation in the mouse genome (not shown). Since the bands corresponding to the integrated transgene in lineages 1.3.32 and 1.3.46 show comparable signal intensities by Southern blot (Fig. 2A) , it is likely that lineage 1.3.46 contains only two or three copies of the integrated transgene. These structures contain the regulatory and structural elements required for expression of all of the viral gene products and for replication of the viral genome.
HBV replicative intermediates. As can be seen in Fig. 2A , Southern blot analysis of total DNA extracted from liver and kidney tissues of lineages 1.3.32 and 1.3.46 shows a smear of low-molecular-weight HBV DNA molecules, in which it is possible to distinguish three bands that correspond to the expected sizes of the relaxed circular DNA, the double-stranded linear DNA, and the single-stranded DNA. As mentioned above, lineage 1.3.32 contains a single copy of the integrated transgene per cell (and two or three copies are present in lineage 1.3.46). Since approximately 20 to 30% of the hepatocytes sustain high-level HBV replication in these animals (see below) and since the hepatocytes represent about 80% of total liver cells, by comparing the signal intensity of the integrated transgene with those for HBV replicative forms (Fig. 2B) , we estimated that 100 to 200 copies of HBV replicative intermediates are present in each HBV replicating hepatocyte. This estimate is consistent with the results of an independent experiment in which HBV replicative intermediates were quantitated by a comparison with serial dilutions of a purified 3.2-kb HBV DNA fragment (not shown).
Total hepatic DNA from the transgenic lineages was compared with DNAs from previously described transgenic mice produced by other investigators to evaluate the relative efficiency of HBV replication in the various strains of mice. As shown in Fig. 2 , HBV replication in lineages 1.3.32 and 1.3.46 was 10-to 100-fold greater than that in lineage PC21, described by Farza et al. (9) and that in lineage 1.2HB-BS, produced by . We have also compared the level of HBV replication in our transgenic mice with those in six chronically infected human livers. Both lineages replicate HBV at a level comparable to that in the human liver that showed the highest intrahepatic concentration of HBV DNA replicative intermediates in terms of total cellular DNA per microgram (Fig. 2B ). Developmental expression of viral RNA. The kinetics of hepatic expression of HBV mRNA was examined for lineages 1.3.32 and 1.3.46. As shown in Fig. 3 , viral RNA is not detectable in the liver tissue in newborn mice from lineage 1.3.32. In contrast, the 3.5-and 2.1-kb transcripts are already detectable in the liver tissue in fetal or newborn mice from lineage 1.3.46 (not shown). In both lineages, the level of expression increases steadily during the first several weeks of life, reaching a stable plateau at approximately 4 weeks of age. The 2.4-kb transcript, which is easily detectable at 2 to 3 weeks of age (Fig. 3) , appears to become obscured by the 2.1-kb band as it and the 3.5-kb mRNA increase as the mice reach maturity.
Tissue distribution of viral RNA in adult mice. Northern blot analysis of tissues derived from 8-week-old mice from lineages 1.3.32 and 1.3.46 revealed high-level expression of the 3.5-kb pregenomic RNA and the 2.1-kb envelope mRNA species in liver and kidney tissues in both lineages, with lower-level expression in a variety of other tissues (Fig. 4) .
As stated above, a 2.4-kb mRNA was easily detectable by Northern analysis of liver RNA from 2-to 3-week-old transgenic mice (Fig. 3) , but it became obscured as the abundance of the 2.1-kb transcript increased with time ( Fig. 3 and 4) . Nonetheless, transcripts consistent with this species were detectable by primer extension analysis of liver RNA in the adult animals (not shown). This is consistent with the presence of pre-S1 antigen in the serum (see Table 1 ), since pre-S1 is a unique marker for the large envelope polypeptide which is translated from the 2.4-kb viral mRNA (10) .
A 0.7-kb viral mRNA was never detectable by Northern blot analysis in any tissue in these animals, a finding similar to its low-level expression in the liver during natural infection (19) ; however, multiple bands consistent with this species were detected in the liver by primer extension analysis (not shown), suggesting that all four viral promoters are probably active in these animals.
One additional, currently undefined ϳ3.2-kb transcript was also observed in the kidney of lineage 1.3.32 and in all positive tissues in lineage 1.3.46 (Fig. 4) .
Expression of viral proteins. At the protein level, HBsAg (product of the 2.1-kb mRNA), pre-S1 (product of the 2.4-kb mRNA), and HBeAg (product of the 3.5-kb mRNA) were easily detectable in the serum and urine in both lineages, as shown in Table 1 . As expected, HBcAg (also a product of the 3.5-kb mRNA) was easily detectable in the liver and kidney by immunohistochemical staining (Fig. 5) , and it was also present at lower levels in other tissues ( Table 2 ). The 17-kDa precore protein (HBeAg) was not detectable in total protein extracts from transgenic-mouse liver or kidney by Western blot analysis (data not shown), indicating that intracellular retention of the precore protein is not detectable at this level in the transgenic mouse. Only small amounts of HBsAg were detectable in the cytoplasm of centrilobular hepatocytes (Table 2) , consistent with production of the rapidly secretable, HBsAg-containing middle and major envelope proteins by translation of the abundant 2.1-kb mRNA. Immunoreactive X protein was not detectable in liver or kidney by Western blot analysis (not shown). Distribution of HBcAg in the liver and kidney. Both lineages displayed the same subcellular and architectural distribution of HBcAg in the liver and kidney. As illustrated in Fig. 5A for lineage 1.3.32, HBcAg is present in the nuclei of almost all of the hepatocytes distributed widely throughout the hepatic lobule from the centrilobular region around central veins to the periportal region around the portal tracts. At the cytoplasmic level, however, HBcAg is detectable mainly in the centrilobular hepatocytes surrounding the central veins, despite the fact that all of the hepatocytes contain abundant HBcAg in their nuclei. As illustrated in the inset in Fig. 5 , the cellular HBcAg appears to be particulate since typical 25-to 30-nm HBcAg particles (core particles and nucleocapsid particles) were detected in both the cytoplasm and the nucleus in the centrilobular hepatocytes. HBcAg is also present in the nucleus and the cytoplasm of the proximal convoluted tubules of the kidney, especially the deep cortical tubules immediately adjacent to the renal medulla, indicating the existence of important host influences on viral gene expression in these animals (Fig. 5B) .
Differential expression and replication of HBV in the cytoplasm in centrilobular hepatocytes. The basis for the preferential expression of cytoplasmic HBcAg in the centrilobular hepatocytes was examined by in situ hybridization analysis using antisense probes that are specific for either all HBV mRNAs (Fig. 6A) or the 3.5-kb viral mRNA (Fig. 6B) . As shown in Fig. 6A , HBV RNA is detectable in virtually all of the hepatocytes when a probe that spans sequences on the noncoding strand of the X region of HBV (between residues 1243 and 1948) was used. When a probe specific for the 3.5-kb viral mRNA (between residues 2139 and 2800) was used (Fig. 6B) , we observed a stronger expression of this transcript in the centrilobular region, in keeping with the presence of HBcAg in the cytoplasm in these cells (Fig. 5A ) and suggesting that higher-level expression is required for HBcAg to accumulate P-labeled antisense probe that covers the X region of HBV was used on transgenic-mouse (A) and nontransgenic-mouse (D) liver tissues. A 33 P-labeled antisense probe specific for the 3.5-kb mRNA was used on transgenic-mouse (B) and nontransgenic-mouse (E) liver tissues. A to detectable levels in the cytoplasm than that required in the nucleus.
When the same tissue was RNase treated and probed by an HBV-specific sense probe that can detect the viral minusstrand DNA, the signal was also stronger in the cytoplasm in the centrilobular hepatocytes (Fig. 6C) . The cytoplasmic compartmentalization of minus-strand viral DNA was confirmed and extended by Southern blot analysis of DNA prepared from 8 ϫ 10 6 isolated nuclei and the cytoplasmic fraction derived from 4 ϫ 10 5 liver cells from these animals. In this study, using a total HBV DNA probe capable of detecting viral plus and minus strands, DNA species corresponding in size to the linear single-stranded, linear double-stranded, and relaxed circular double-stranded forms of the HBV genome were detectable in the total liver extract (Fig. 7, lanes 1 and 2) and in the cytoplasmic compartment of the liver, where they were shown to be DNase resistant (Fig. 7, lanes 5 and 6) , but not in the nucleus (Fig. 7, lanes 3 and 4) . These results suggest that viral replication is restricted to a DNase-resistant compartment in the cytoplasm in these animals and that viral DNA is not detectable in the nucleus by these techniques.
Structure of the replicative intermediates. To examine the structure of the DNA replicative intermediates, cytoplasmic DNA was extracted from the livers of both transgenic lineages and from the liver of an infected patient and either heated at 100ЊC for 5 min or treated with Klenow polymerase before gel electrophoresis. Southern blot analysis was carried out with HBV strand-specific probes. In all instances, HBV replicative intermediates in the transgenic-mouse and human livers were identical in structure (not shown).
Detection of cccDNA. The presence of the cccDNA species, which normally serves as the intranuclear transcriptional template for viral gene expression during HBV infection (33) , was tested in the transgenic-mouse liver by Southern blot analysis of non-protein-bound nucleic acid extracts. We compared the contents of cccDNA and replicative intermediates in transgenic-mouse and infected human livers. In this experiment the cccDNA and replicative intermediate preparations were derived from the same amount of liver tissue, and equal amounts of human and mouse livers were used to prepare these extracts. As shown in Fig. 8 , cccDNA was not detectable in the transgenic-mouse liver, while it was readily detectable in the human liver by Southern blot analysis, despite the fact that the levels of viral replication were equivalent in these tissues. The reason for this important difference is not clear at this time.
Circulating viral particles. To determine whether potentially infectious viral particles are formed and secreted into the blood of these mice, serum was analyzed for the presence of HBV DNA, endogenous polymerase activity, and sedimentable particles displaying the ultrastructural characteristics of complete virions (Dane particles).
Serum HBV DNA content was analyzed by two different dot blot experiments. In the first instance, 300 l of filtered serum was treated with DNase prior to dot blot hybridization with an HBV-specific probe in order to eliminate any transgene DNA contaminating the specimen because of normal cell turnover or tissue damage during phlebotomy, and the results were compared with a serially diluted HBV DNA standard. As shown in Fig. 9A , this analysis yielded ϳ9 ϫ 10 7 HBV genome eq/ml in lineage 1.3.46 (ϳ300 pg of HBV DNA per ml) and ϳ3 ϫ 10 7 HBV genome eq/ml in lineage 1.3.32 (ϳ100 pg of HBV DNA per ml). HBV DNA was undetectable in the serum of an HBV transgenic-mouse lineage (pFC80-219) that does not replicate the viral genome, even though this serum was not treated with DNase. This illustrates that the signal in lineages 1.3.32 and 1.3.46 was not derived from contaminating genomic DNA. In the second instance, HBV DNA quantitation yielded an estimate of ϳ100 pg of HBV DNA per ml in lineage 1.3.32. This is approximately 20% of the HBV DNA concentration in the serum of a chimpanzee at the peak of infection with HBV produced from a cloned HBV DNA genome identical to the one used here as transgene (Fig. 9B) . The association of DNA polymerase activity with HBV genomes was demonstrated by restriction endonuclease digestion of the 32 P-labeled reaction product. As shown in Fig. 9C , digestion of the transgenicmouse-derived reaction product with EcoRI, BglII, and BamHI yielded labeled fragments displaying the same mobility as a similarly treated reaction product derived from the serum of the chimpanzee infected with HBV with an identical sequence (35) . 
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Ultrastructural analysis of endogenous polymerase-positive fractions of ultracentrifuged transgenic-mouse serum captured on anti-pre-S1 coated grids revealed the presence of characteristic 42-nm particles (Fig. 10A ) that are morphologically indistinguishable from Dane particles purified from infected human serum (Fig. 10B) . These particles were not detectable in the same fractions applied to grids that had not been coated with anti-pre-S1 antibody, nor were they detected in the corresponding endogenous polymerase-negative fractions from nontransgenic-mouse serum applied to antibody-coated grids (not shown).
Histopathological findings. Animals from lineages 1.3.32 and 1.3.46 have been monitored histologically for over 1 year without evidence of pathological changes in any organ, especially the liver and kidney (not shown).
DISCUSSION
HBV transgenic mice whose hepatocytes replicate the virus at high levels without any evidence of cytopathology have been produced. Approximately 100 to 200 copies of HBV replicative intermediates were detectable in each hepatocyte. This compares favorably with the estimate of 100 to 700 copies per infected hepatocyte during acute woodchuck hepatitis virus infection (18) . Furthermore, the estimated 10 7 to 10 8 viral genomes detectable per ml of serum in these animals compares favorably with the concentration of virus present in the sera of chronically infected humans (28) . These results confirm the noncytopathic behavior of HBV in healthy carriers (16) .
High-level viral gene expression and replication were observed in the liver and kidney in three independent lineages produced with a terminally redundant, 1.3ϫ genome length transgene that starts just upstream of the X promoter and enhancer I and ends just downstream of the unique HBV polyadenylation site. Slightly shorter constructs lacking these upstream elements, including lineage 1.2HB-BS produced by Araki et al. (1), consistently yielded lower-level expression and much lower levels of replication, which were preferentially detectable in the kidney tissue instead of the liver tissue in the corresponding animals. These data suggest that the transgene structure may contribute to the level of liver-specific HBV gene expression in these animals.
The above finding is interesting because the extra sequences that are uniquely present at the 5Ј end of the 1.3 genome construct integrated in the mouse genome encompass the signals needed for expression of the X gene. Since the X gene is known to be important for woodchuck hepatitis virus replication in the liver in vivo (36) , the level of X gene expression might also influence the level of viral replication in the liver in these mice. Although low-level X mRNA is detectable in the liver in the 1.3 series of animals by primer extension analysis, we do not have direct evidence to prove that this notion is correct at this time, since we have been unable to detect X protein in the liver in these animals. Additionally, the 1.3, but not the 1.1 or 1.2, series of animals contains an extra copy of the entire HBV enhancer I at the 5Ј end of the integrated transgene. This factor could be responsible for higher-level liver gene expression in these animals.
The family of 3.5-kb HBV transcripts normally serves as the mRNA for the viral nucleocapsid proteins (HBcAg and HBeAg) and for the viral polymerase protein, and it also serves as the viral pregenome which is reverse transcribed by the polymerase to produce the first strand of viral DNA during viral replication (30) . The 2.4-, 2.1-, and 0.7-kb transcripts normally serve as the mRNAs for the viral large and middle/ major envelope proteins and the X protein, respectively. Dur- DNase-resistant HBV DNAs extracted from 300-l serum samples from lineages 1.3.46 and 1.3.32 are shown below. As a negative control, 300 l of untreated serum from a lineage (pFC80-219) that does not replicate the viral genome was also included. (B) In an independent experiment, the HBV DNA content of 100 l of transgenic-mouse serum (lineage 1.3.32) was compared with the HBV DNA content of 100 l of serum from a chimpanzee acutely infected with HBV (35) . The signals for serial dilutions of a plasmid of known HBV DNA concentration (expressed in picograms) are shown above. (C) The endogenous polymerase activity present in the ultracentrifuged pellet derived from 1 ml of transgenic-mouse serum (lineage 1.3.32) was compared with that in 100 l of chimpanzee serum. The 32 P-radiolabeled endogenously elongated HBV DNA products were analyzed by electrophoresis in a 1.5% agarose gel containing 1% SDS before and after digestion with selected restriction enzymes. Lane M, molecular weight markers.
ing normal viral replication, the 3.5-and 2.1-kb transcripts are most abundant and present in roughly equimolar quantities, while the 2.4-kb transcript is a minor species and the 0.7-kb mRNA is not detectable (10) .
All of these transcripts are expressed in the liver in the current lineages in the proportions and abundance typical of natural HBV infection ( Fig. 3 and 4) , and they are also abundant in the subset of proximal convoluted renal tubules that are located deep in the renal cortex immediately adjacent to the medulla (Fig. 4) . In addition, viral RNA is present in trace amounts in scattered tissues and absent from other tissues (Fig.  4) , presumably because of the influence of host factors (e.g., transcription factors) that regulate viral gene expression. Along these lines, it may be germane that hepatocyte nuclear factor 1 alpha (HNF 1 ␣) is known to be preferentially expressed in hepatocytes and in the juxtamedullary proximal convoluted tubules of the kidney (29) .
Presumably for similar reasons, the 3.5-kb HBV mRNA is more abundant in the centrilobular hepatocytes than elsewhere in the hepatic lobule in these transgenic mice (Fig. 6B) . This is reflected in the expression of HBcAg particles in the cytoplasm of the centrilobular hepatocytes, i.e., the same cells that contain large amounts of replicative DNA forms in the liver lobule (Fig. 6C) . Collectively, these results strongly suggest that viral replication is occurring in the cytoplasmic nucleocapsid particles in the centrilobular hepatocytes of these animals and, by inference, in the HBcAg-positive cytoplasm of the juxtamedullary proximal convoluted tubules of the kidney.
The data also indicate that the viral polymerase protein is expressed in these mice and that it is packaged in the nucleocapsid particles together with the 3.5-kb pregenomic RNA, since the minus-strand DNA is known to be produced by reverse transcription of the 3.5-kb pregenomic RNA by the viral polymerase protein inside nucleocapsid particles (30) . Additionally, the data indicate that an expression threshold for HBcAg, viral polymerase, and 3.5-kb pregenomic RNA must be reached before these events can occur.
Finally, the results suggest that the intranuclear nucleocapsid particles present in the liver and kidney in these animals ( Fig. 7) do not contain viral DNA (i.e., they are empty). When considered together with the fact that most of the hepatocytes contain HBcAg in their nuclei in these and other transgenic mice that we have previously described (13), the current observations indicate that the intranuclear HBcAg particles form de novo in the nucleus and that they are not transported there from the cytoplasm, even in cells that also contain cytoplasmic HBcAg. This conclusion confirms our previous evidence (13) that HBcAg particles do not cross the nuclear membrane in either direction in transgenic mice, and it suggests that HBcAg particles do not carry the viral DNA into the nucleus during If this finding extends to infected human liver, it implies that nucleocapsid disassembly must occur at the cytoplasmic face of the nuclear membrane to allow the viral DNA to enter the nucleus. If this notion is correct, it raises serious questions about the significance of the intranuclear HBcAg particles during the viral life cycle. As a consequence of efficient viral replication, it is not surprising that ultrastructurally complete viral particles morphologically indistinguishable from human Dane particles were detected in the transgenic mouse serum (between 3 ϫ 10 7 and 9 ϫ 10 7 viral particles per ml). This finding further indicates that the HBV life cycle can be efficiently completed in the transgenic-mouse hepatocyte.
Surprisingly, HBV cccDNA, the normal viral transcriptional template during natural infection, is not readily detectable by direct Southern blot analysis in the hepatocyte nucleus in these animals (Fig. 8) . In preliminary experiments, however, using a PCR-based technique that has been previously shown to selectively amplify cccDNA (21), HBV cccDNA was detectable in total hepatic DNAs from both transgenic lineages (not shown). The results of these studies will be reported elsewhere.
It is important to reiterate that similar transgenic mice have been produced by other investigators in recent years (1, 9) . While those animals clearly demonstrated that HBV replication can occur in the transgenic murine hepatocyte, their experimental value has been limited because they replicate the virus at a very low level. The high level of HBV replication in the new lineages now creates the opportunity to examine the influence of viral and host factors on HBV replication and pathogenesis and to assess the potential of pharmacological agents and physiological processes, including the immune response, to control HBV replication in a genetically defined small-animal system.
